Communiqués MannKind Corporation

Actions

MNKD

US56400P7069

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 20:53:20 29/07/2026			Varia. 5j.	Varia. 1 janv.
3,925 ^USD	+0,38%		+0,39%	-32,01%

16:13	MannKind : l'étude de phase 1b montre que son traitement contre la fibrose pulmonaire idiopathique est globalement sûr et bien toléré	MT
15:30	MannKind Corporation annonce des résultats positifs pour l'étude de phase 1b INFLO-1 et fait le point sur le développement clinique du nintedanib DPI dans la FPI	CI

Communiqués

12:30	MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF	AQ
28/07	MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026	AQ
27/07	MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease	AQ
24/07	FDA approves Furoscix ReadyFlow for at-home treatment of edema	AQ
24/07	MannKind Announces $50 Million Private Placement	AQ
24/07	MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease	AQ
23/06	MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D	AQ
06/06	Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems	AQ
03/06	MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF	AQ
29/05	MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval	AQ
29/05	MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes	AQ
27/05	MannKind to Present at Jefferies Global Healthcare Conference	AQ
27/05	MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems	AQ
07/05	MannKind : First Quarter 2026 Earnings Call Presentation (dee743)	PU
06/05	MannKind: Q1 Earnings Snapshot	AQ
06/05	MannKind Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
29/04	MannKind to Report First Quarter 2026 Financial Results on May 6, 2026	AQ
09/03	MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026	AQ
05/03	MannKind Announces Settlement of Convertible Senior Notes	AQ
04/03	MannKind to Participate in Upcoming Investor Conferences	AQ
26/02	MannKind: Q4 Earnings Snapshot	AQ
26/02	MannKind : Fourth Quarter 2025 Earnings Call Presentation (83e8f5)	PU
26/02	MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
19/02	MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
18/02	MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	AQ